As previously disclosed in the Current Report on Form 8-K filed on October 13, 2022 by Imara Inc.
(Imara), on October 13, 2022, Imara, Iguana Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Imara (Merger Sub), and Enliven Therapeutics, Inc., a Delaware corporation (Enliven),
entered into an Agreement and Plan of Merger (the Merger Agreement), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and
into Enliven, with Enliven continuing as a wholly owned subsidiary of Imara and the surviving corporation of the merger (the Merger).
On
November 28, 2022, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (the HSR Act) applicable to the Merger, expired without extension or a request for additional information or documentary material. The
expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the Merger.
Cautionary Note Regarding
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements (including
within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the Securities Act)) concerning Enliven, Imara, the proposed transactions and
other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Imara and Enliven, as well
as assumptions made by, and information currently available to, management of Imara and Enliven. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and
include words such as may, will, should, would, expect, anticipate, plan, likely, believe, estimate, project,
intend, and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words.
Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, expectations regarding the proposed Merger. Forward-looking statements are based on current beliefs and assumptions
that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation the
risks related to the proposed merger included in the registration statement on Form S-4 that was filed with the Securities and Exchange Commission (the SEC) and will be included in the definitive
proxy statement/prospectus if and when it becomes available in connection with the proposed transaction, and the risk factors included in Imaras most recent Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q and Current Reports on Form 8-K filed with the SEC. Imara and Enliven can give no assurance that the conditions to the proposed transactions will be
satisfied. Except as required by applicable law, Imara and Enliven undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or
otherwise.
No Offer or Solicitation
This Current
Report on Form 8-K is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the
solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be
made except by means of a prospectus meeting the requirements of